FNDC5 and pulmonary arterial hypertension: Our previous study on irisin revealed an association between low plasma irisin levels and adverse clinical outcome in PAH, which has been a cohort validation for present study.[13] However, a more intensive study on the effect of irisin on PAH clinical risk stratification and the detailed mechanism underlying the protective role of irisin deserves further investigation.